Yonsei Med J.  2013 Jan;54(1):231-237. 10.3349/ymj.2013.54.1.231.

The Influence of the Severity of Chronic Virus-Related Liver Disease on Propofol Requirements during Propofol-Remifentanil Anesthesia

• Wu J
• Huang SQ
• Chen QL
• Zheng SS

• KMID: 1776944
• DOI: http://doi.org/10.3349/ymj.2013.54.1.231

Abstract

PURPOSE
The purpose of this study was to investigate the influence of chronic virus-related liver disease severity on propofol requirements.
MATERIALS AND METHODS
In this study, 48 male patients with chronic hepatitis B infection were divided into three groups according to Child-Turcotte-Pugh classification of liver function (groups A, B, and C with mild, moderate and severe liver disease, respectively). After intubation, propofol concentration was adjusted by +/-0.3 microg/mL increments to maintain bispectral index in the range of 40-60. Target propofol concentrations at anesthesia initiation, pre-intubation and pre-incision were recorded.
RESULTS
The initial concentration used in group C was significantly lower than that used in group A or B (p<0.05), whereas no difference was observed between groups A and B. At pre-intubation, the actual required concentration of propofol increased significantly (3.2 microg/mL) in group A (p<0.05), which lead to significant differences between the groups (p<0.05). At pre-incision, the requirements for propofol decreased significantly in both groups A and B (3.0 microg/mL and 2.7 microg/mL, respectively) compared with those at pre-intubation (p<0.05), and were significantly different for all three groups (p<0.05), with group C demonstrating the lowest requirement (2.2 microg/mL). The required concentrations of propofol at pre-incision were similar to those at induction.
CONCLUSION
In this study, propofol requirements administered by target-controlled infusion to maintain similar depths of hypnosis were shown to depend on the severity of chronic virus-related liver dysfunction. In other words, patients with the most severe liver dysfunction required the least amount of propofol.

Keyword

Propofol; liver disease; electroencephalography

MeSH Terms

Adult
Anesthesia
Anesthetics, Intravenous/*administration & dosage
Chronic Disease
Electroencephalography
Hepatitis B, Chronic/complications/drug therapy/*surgery
Humans
Liver Diseases/*complications/surgery
Male
Middle Aged
Piperidines/*administration & dosage
Propofol/*administration & dosage
Virus Diseases/*complications/surgery
Anesthetics, Intravenous
Piperidines
Propofol

Reference

1. Ziser A, Plevak DJ. Morbidity and mortality in cirrhotic patients undergoing anesthesia and surgery. Curr Opin Anaesthesiol. 2001. 14:707–711.

2. Servin F, Cockshott ID, Farinotti R, Haberer JP, Winckler C, Desmonts JM. Pharmacokinetics of propofol infusions in patients with cirrhosis. Br J Anaesth. 1990. 65:177–183.

3. Schnider TW, Minto CF, Shafer SL, Gambus PL, Andresen C, Goodale DB, et al. The influence of age on propofol pharmacodynamics. Anesthesiology. 1999. 90:1502–1516.

4. Schüttler J, Ihmsen H. Population pharmacokinetics of propofol: a multicenter study. Anesthesiology. 2000. 92:727–738.

5. Irwin MG, Hui TW, Milne SE, Kenny GN. Propofol effective concentration 50 and its relationship to bispectral index. Anaesthesia. 2002. 57:242–248.

6. Johnson KB, Egan TD, Kern SE, McJames SW, Cluff ML, Pace NL. Influence of hemorrhagic shock followed by crystalloid resuscitation on propofol: a pharmacokinetic and pharmacodynamic analysis. Anesthesiology. 2004. 101:647–659.

7. Xu Z, Liu F, Yue Y, Ye T, Zhang B, Zuo M, et al. C50 for propofol-remifentanil target-controlled infusion and bispectral index at loss of consciousness and response to painful stimulus in Chinese patients: a multicenter clinical trial. Anesth Analg. 2009. 108:478–483.

8. Wu J, Zhu SM, He HL, Weng XC, Huang SQ, Chen YZ. Plasma propofol concentrations during orthotopic liver transplantation. Acta Anaesthesiol Scand. 2005. 49:804–810.

9. Takizawa D, Sato E, Hiraoka H, Tomioka A, Yamamoto K, Horiuchi R, et al. Changes in apparent systemic clearance of propofol during transplantation of living related donor liver. Br J Anaesth. 2005. 95:643–647.

10. Amorós A, Aparicio JR, Garmendia M, Casellas JA, Martínez J, Jover R. Deep sedation with propofol does not precipitate hepatic encephalopathy during elective upper endoscopy. Gastrointest Endosc. 2009. 70:262–268.

11. Riphaus A, Lechowicz I, Frenz MB, Wehrmann T. Propofol sedation for upper gastrointestinal endoscopy in patients with liver cirrhosis as an alternative to midazolam to avoid acute deterioration of minimal encephalopathy: a randomized, controlled study. Scand J Gastroenterol. 2009. 44:1244–1251.

12. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973. 60:646–649.

13. Marsh B, White M, Morton N, Kenny GN. Pharmacokinetic model driven infusion of propofol in children. Br J Anaesth. 1991. 67:41–48.

14. Struys MM, De Smet T, Depoorter B, Versichelen LF, Mortier EP, Dumortier FJ, et al. Comparison of plasma compartment versus two methods for effect compartment--controlled target-controlled infusion for propofol. Anesthesiology. 2000. 92:399–406.

15. Minto CF, Schnider TW, Egan TD, Youngs E, Lemmens HJ, Gambus PL, et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Anesthesiology. 1997. 86:10–23.

16. Chernik DA, Gillings D, Laine H, Hendler J, Silver JM, Davidson AB, et al. Validity and reliability of the Observer's Assessment of Alertness/Sedation Scale: study with intravenous midazolam. J Clin Psychopharmacol. 1990. 10:244–251.

17. Veselis RA, Glass P, Dnistrian A, Reinsel R. Performance of computer-assisted continuous infusion at low concentrations of intravenous sedatives. Anesth Analg. 1997. 84:1049–1057.

18. Khamaysi I, William N, Olga A, Alex I, Vladimir M, Kamal D, et al. Sub-clinical hepatic encephalopathy in cirrhotic patients is not aggravated by sedation with propofol compared to midazolam: a randomized controlled study. J Hepatol. 2011. 54:72–77.

19. Wang CH, Chen CL, Cheng KW, Huang CJ, Chen KH, Wang CC, et al. Bispectral index monitoring in healthy, cirrhotic, and end-stage liver disease patients undergoing hepatic operation. Transplant Proc. 2008. 40:2489–2491.

20. Li Z, Chen X, Meng J, Deng L, Ma H, Csete M, et al. ED50 and recovery times after propofol in rats with graded cirrhosis. Anesth Analg. 2012. 114:117–121.

21. Milne SE, Kenny GN, Schraag S. Propofol sparing effect of remifentanil using closed-loop anaesthesia. Br J Anaesth. 2003. 90:623–629.

22. Koitabashi T, Johansen JW, Sebel PS. Remifentanil dose/electroencephalogram bispectral response during combined propofol/regional anesthesia. Anesth Analg. 2002. 94:1530–1533.

23. Gan TJ, Glass PS, Windsor A, Payne F, Rosow C, Sebel P, et al. BIS Utility Study Group. Bispectral index monitoring allows faster emergence and improved recovery from propofol, alfentanil, and nitrous oxide anesthesia. Anesthesiology. 1997. 87:808–815.

24. Bauer M, Wilhelm W, Kraemer T, Kreuer S, Brandt A, Adams HA, et al. Impact of bispectral index monitoring on stress response and propofol consumption in patients undergoing coronary artery bypass surgery. Anesthesiology. 2004. 101:1096–1104.

25. Dershwitz M, Hoke JF, Rosow CE, Michałowski P, Connors PM, Muir KT, et al. Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease. Anesthesiology. 1996. 84:812–820.

26. Navapurkar VU, Archer S, Gupta SK, Muir KT, Frazer N, Park GR. Metabolism of remifentanil during liver transplantation. Br J Anaesth. 1998. 81:881–886.

27. Lichtenbelt BJ, Mertens M, Vuyk J. Strategies to optimise propofol-opioid anaesthesia. Clin Pharmacokinet. 2004. 43:577–593.

28. Wang LP, McLoughlin P, Paech MJ, Kurowski I, Brandon EL. Low and moderate remifentanil infusion rates do not alter target-controlled infusion propofol concentrations necessary to maintain anesthesia as assessed by bispectral index monitoring. Anesth Analg. 2007. 104:325–331.

29. Iwakiri H, Nishihara N, Nagata O, Matsukawa T, Ozaki M, Sessler DI. Individual effect-site concentrations of propofol are similar at loss of consciousness and at awakening. Anesth Analg. 2005. 100:107–110.

30. Wakeling HG, Zimmerman JB, Howell S, Glass PS. Targeting effect compartment or central compartment concentration of propofol: what predicts loss of consciousness? Anesthesiology. 1999. 90:92–97.

31. Minto CF, Schnider TW, Gregg KM, Henthorn TK, Shafer SL. Using the time of maximum effect site concentration to combine pharmacokinetics and pharmacodynamics. Anesthesiology. 2003. 99:324–333.

32. Vuyk J, Engbers FH, Lemmens HJ, Burm AG, Vletter AA, Gladines MP, et al. Pharmacodynamics of propofol in female patients. Anesthesiology. 1992. 77:3–9.